An eye-opener? GLP-1 RAs linked to reduced risk of 42 conditions from dementia to infections
But the observational study also found a potential increased risk for low blood pressure, arthritis and nausea.
A major study of nearly two million patients with type 2 diabetes has highlighted the potential wide-ranging health benefits of GLP-1 receptor agonists — but also potential risks.
Researchers mapped links between the medications and 175 health outcomes, comparing them to those of patients taking other common antiglycaemics such as sulfonylureas, dipeptidyl peptidase-4 inhibitors or SGLT2 inhibitors, and those continuing with their usual care.
